This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2017 Nov;46(10):1016-1017.

doi: 10.1111/apt.14325.

Editorial: rifaximin in cirrhosis - is it what we've been waiting for?

J Huang¹

Affiliations

PMID: 29052858
DOI: 10.1111/apt.14325

Editorial

Editorial: rifaximin in cirrhosis - is it what we've been waiting for?

J Huang. Aliment Pharmacol Ther. 2017 Nov.

. 2017 Nov;46(10):1016-1017.

doi: 10.1111/apt.14325.

Author

J Huang¹

Affiliation

¹ University of Rochester Medical Center, Rochester, NY, USA.

PMID: 29052858
DOI: 10.1111/apt.14325

No abstract available

PubMed Disclaimer

Comment in

Editorial: rifaximin in cirrhosis-is this what we've been waiting for? Authors' reply.
Kang SH, Lee YB, Lee JH. Kang SH, et al. Aliment Pharmacol Ther. 2017 Nov;46(10):1017-1018. doi: 10.1111/apt.14343. Aliment Pharmacol Ther. 2017. PMID: 29052857 No abstract available.

Comment on

Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.
Kang SH, Lee YB, Lee JH, Nam JY, Chang Y, Cho H, Yoo JJ, Cho YY, Cho EJ, Yu SJ, Kim MY, Kim YJ, Baik SK, Yoon JH. Kang SH, et al. Aliment Pharmacol Ther. 2017 Nov;46(9):845-855. doi: 10.1111/apt.14275. Epub 2017 Aug 24. Aliment Pharmacol Ther. 2017. PMID: 28836723

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information